These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17294248)

  • 1. Structure and reaction based evaluation of synthetic accessibility.
    Boda K; Seidel T; Gasteiger J
    J Comput Aided Mol Des; 2007 Jun; 21(6):311-25. PubMed ID: 17294248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RASA: a rapid retrosynthesis-based scoring method for the assessment of synthetic accessibility of drug-like molecules.
    Huang Q; Li LL; Yang SY
    J Chem Inf Model; 2011 Oct; 51(10):2768-77. PubMed ID: 21932860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemists.
    Bonnet P
    Eur J Med Chem; 2012 Aug; 54():679-89. PubMed ID: 22749644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in de novo design strategy for practical lead identification.
    Honma T
    Med Res Rev; 2003 Sep; 23(5):606-32. PubMed ID: 12789688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular complexity analysis of de novo designed ligands.
    Boda K; Johnson AP
    J Med Chem; 2006 Oct; 49(20):5869-79. PubMed ID: 17004702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions.
    Ertl P; Schuffenhauer A
    J Cheminform; 2009 Jun; 1(1):8. PubMed ID: 20298526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wisdom of crowds for synthetic accessibility evaluation.
    Baba Y; Isomura T; Kashima H
    J Mol Graph Model; 2018 Mar; 80():217-223. PubMed ID: 29414041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility.
    Huang Q; Li LL; Yang SY
    J Mol Graph Model; 2010 Jun; 28(8):775-87. PubMed ID: 20206562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen.
    Firth-Clark S; Willems HM; Williams A; Harris W
    J Chem Inf Model; 2006; 46(2):642-7. PubMed ID: 16562994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding-Site Compatible Fragment Growing Applied to the Design of β
    Chevillard F; Rimmer H; Betti C; Pardon E; Ballet S; van Hilten N; Steyaert J; Diederich WE; Kolb P
    J Med Chem; 2018 Feb; 61(3):1118-1129. PubMed ID: 29364664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
    Dessalew N; Bharatam PV
    Bioorg Med Chem; 2007 Jun; 15(11):3728-36. PubMed ID: 17399989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYNOPSIS: SYNthesize and OPtimize System in Silico.
    Vinkers HM; de Jonge MR; Daeyaert FF; Heeres J; Koymans LM; van Lenthe JH; Lewi PJ; Timmerman H; Van Aken K; Janssen PA
    J Med Chem; 2003 Jun; 46(13):2765-73. PubMed ID: 12801239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing synthetic accessibility of chemical compounds using machine learning methods.
    Podolyan Y; Walters MA; Karypis G
    J Chem Inf Model; 2010 Jun; 50(6):979-91. PubMed ID: 20536191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation.
    Wei L; Wen W; Rao L; Huang Y; Lei M; Liu K; Hu S; Song R; Ren Y; Wan J
    J Chem Inf Model; 2020 Sep; 60(9):4388-4402. PubMed ID: 32233478
    [No Abstract]   [Full Text] [Related]  

  • 16. Second-generation de novo design: a view from a medicinal chemist perspective.
    Zaliani A; Boda K; Seidel T; Herwig A; Schwab CH; Gasteiger J; Claussen H; Lemmen C; Degen J; Pärn J; Rarey M
    J Comput Aided Mol Des; 2009 Aug; 23(8):593-602. PubMed ID: 19562260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing active template molecules by combining computational de novo design and human chemist's expertise.
    Lameijer EW; Tromp RA; Spanjersberg RF; Brussee J; Ijzerman AP
    J Med Chem; 2007 Apr; 50(8):1925-32. PubMed ID: 17367122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking and scoring--theoretically easy, practically impossible?
    Coupez B; Lewis RA
    Curr Med Chem; 2006; 13(25):2995-3003. PubMed ID: 17073642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid evaluation of synthetic and molecular complexity for in silico chemistry.
    Allu TK; Oprea TI
    J Chem Inf Model; 2005; 45(5):1237-43. PubMed ID: 16180900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.